Merkel Cell Carcinoma Clinical Trials 2024

What are the top hospitals conducting merkel cell carcinoma research?

When it comes to clinical trials for the rare and aggressive skin cancer known as Merkel cell carcinoma, several top hospitals are leading the way. In Seattle, the University of Washington - Seattle Cancer Care Alliance is making significant strides with two ongoing trials focused on this challenging condition. Since recording their first trial in 2014, they have conducted a total of four studies dedicated to understanding and treating Merkel cell carcinoma. Similarly, Memorial Sloan Kettering Cancer Center in New york has also embraced this important research area with two active clinical trials and an impressive track record of ten completed studies since 2014.

Down in Tampa, Moffitt Cancer Center is another standout institution when it comes to advancing our knowledge of Merkel cell carcinoma. With two ongoing clinical trials and a decade-long history dating back to their initial investigation in 2014, Moffitt continues to contribute valuable insights into this complex disease. Meanwhile, Penn Medicine in Philadelphia may have fewer ongoing trials for Merkel cell carcinoma but still plays an essential role by conducting one active study at present while marking their entry into research on this specific type only last year in 2023.

Last but not least is M D Anderson Cancer Center located in Houston. Although they currently have one active trial focused on Merkel cell carcinoma, their impact shouldn't be underestimated as they've already completed six previous investigations since delving into research for this disease backin 2010.

These medical institutions are united by their commitment to unraveling the mysteries surrounding Merkel cell carcinoma through rigorous scientific inquiry. By pushing boundaries and exploring new treatment avenues through clinical trials, these hospitals bring hope to patients diagnosed with this rare form of cancer across different locations throughout the United States

Which are the best cities for merkel cell carcinoma clinical trials?

When it comes to merkel cell carcinoma clinical trials, several cities are at the forefront of research and development. New york, New York offers 7 active trials that investigate treatments such as KRT-232, Pembrolizumab (MK-3475), and Comprehensive Ablative Radiation Therapy. Anchorage, Alaska also has 7 ongoing trials focusing on Pembrolizumab and other potential interventions. Chicago, Illinois follows closely behind with 6 active studies exploring Pembrolizumab, KRT-232, Retifanlimab, among others. Des Moines in Iowa is another city with 6 active trials investigating treatments like Pembrolizumab. Lastly, Louisville in Kentucky contributes to the research landscape with 4 ongoing trials exploring various treatment options including Pembrolizumab and Retifanlimab. These cities provide individuals diagnosed with merkel cell carcinoma access to cutting-edge clinical trials that strive for advancements in care and improve patient outcomes.

Which are the top treatments for merkel cell carcinoma being explored in clinical trials?

Merkel cell carcinoma, a rare but aggressive form of skin cancer, is the focus of ongoing clinical trials exploring various treatment options. Among the top contenders are:

• Pembrolizumab: Currently being tested in three active trials and with a total of 14 all-time merkel cell carcinoma trials since its debut in 2014.
• Radiation therapy: A promising approach under investigation in one active trial and having one all-time merkel cell carcinoma trial recorded as well, first listed in 2021.
• Comprehensive Ablative Radiation Therapy: Another radiation-based treatment option currently involved in one active trial and featured in one previous merkel cell carcinoma study since 2021.
• Domatinostat with avelumab combination: Under evaluation through one active trial and two all-time merkel cell carcinoma trials dating back to 2020.
• KRT-232: An innovative experimental drug that has entered the scene more recently with promising results; currently undergoing testing in one active trial alongside its sole all-time merit for treating this type of cancer noted from listings beginning in 2019.

These treatments hold immense potential for improving outcomes for patients battling Merkel Cell Carcinoma.

What are the most recent clinical trials for merkel cell carcinoma?

Recent clinical trials in the field of Merkel cell carcinoma have brought forth promising advancements in treatment options. Among these studies is a Phase 2 trial exploring the effectiveness of pembrolizumab, offering hope for improved outcomes for patients with this aggressive form of skin cancer. Additionally, radiation therapy has shown potential as a viable treatment option in Phase 2 trials. Another study involves cemiplimab-rwlc, which exhibited promise during its Phase 1 trial. These recent developments hold significant potential to enhance the management and prognosis of individuals living with Merkel cell carcinoma.

What merkel cell carcinoma clinical trials were recently completed?

Recent advancements in clinical trials for Merkel cell carcinoma hold promise for improved treatments against this aggressive form of skin cancer. Immunomic Therapeutics, Inc., completed a trial for ITI-3000 in June 2022, showcasing the potential of this therapy. In addition to that, Fate Therapeutics concluded their FT500 trial in February 2019, revealing significant insights into its efficacy. It is worth noting that while these two trials demonstrate recent progress, a previous study sponsored by Ludwig Institute for Cancer Research examined Tremelimumab and was completed back in December 2016. These developments underscore the ongoing pursuit of innovative therapies to combat Merkel Cell Carcinoma and improve patient outcomes.